Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

BACKGROUND: Despite the success of immune checkpoint blockade therapy in the treatment of certain cancer types, only a small percentage of patients with solid malignancies achieve a durable response. Consequently, there is a need to develop novel approaches that could overcome mechanisms of tumor re...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Horn, Lucas A, Riskin, Jeffrey, Hempel, Heidi A, Fousek, Kristen, Lind, Hanne, Hamilton, Duane H, McCampbell, Kristen K, Maeda, Dean Y, Zebala, John A, Su, Zhen, Schlom, Jeffrey, Palena, Claudia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Clinical/Translational Cancer Immunotherapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078948/
https://ncbi.nlm.nih.gov/pubmed/32188703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000326
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak